Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Cabozantinib S-Malate

FDA-approved product (capsule, oral), marketed as Cabometyx, Cabozantinib S-Malate, Cometriq.

Registered studies
45
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Cabozantinib S-Malate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Clear cell renal carcinoma
  • Hepatocellular carcinoma
  • Neoplasm
  • Papillary renal cell carcinoma
  • Papillary thyroid carcinoma
  • Renal cell carcinoma
  • Thyroid cancer
  • Thyroid carcinoma
  • Thyroid neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other protein kinase inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA40.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli31.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae24.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis64.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

45registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Cabozantinib S-Malate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-9.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.2 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-10.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Cabozantinib S-Malate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

    NCT02315430 · start 2015-04-01

    Registered record
    Registry ID
    NCT02315430
    Conditions
    Fallopian Tube Clear Cell Adenocarcinoma; Ovarian Clear Cell Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma
    Interventions
    Cabozantinib S-malate; Laboratory Biomarker Analysis
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-04-01
    Completion
    2019-02-09
    Enrolment
    13

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFallopian Tube Clear Cell Adenocarcinoma; Ovarian Clear Cell Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma +1 more
    InterventionCabozantinib S-malate; Laboratory Biomarker Analysis
    PhasePhase 2
    Registry statusCompleted

  • Cabozantinib S-malate in Treating Patients With Metastatic Pheochromocytomas or Paragangliomas That Cannot Be Removed by Surgery

    NCT02302833 · start 2015-02-17

    Registered record
    Registry ID
    NCT02302833
    Conditions
    Locally Advanced Paraganglioma; Metastatic Adrenal Gland Pheochromocytoma; Metastatic Paraganglioma; Regional Adrenal Gland Pheochromocytoma; Unresectable Adrenal Gland Pheochromocytoma; Unresectable Paraganglioma
    Interventions
    Cabozantinib S-malate; Laboratory Biomarker Analysis; Questionnaire Administration
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-02-17
    Completion
    2024-11-12
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLocally Advanced Paraganglioma; Metastatic Adrenal Gland Pheochromocytoma; Metastatic Paraganglioma; Regional Adrenal Gland Pheochromocytoma +2 more
    InterventionCabozantinib S-malate; Laboratory Biomarker Analysis; Questionnaire Administration
    PhasePhase 2
    Registry statusCompleted

  • Cabozantinib S-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma

    NCT02243605 · start 2014-12-19

    Registered record
    Registry ID
    NCT02243605
    Conditions
    Metastatic Ewing Sarcoma; Metastatic Osteosarcoma; Recurrent Ewing Sarcoma; Recurrent Osteosarcoma; Stage III Osteosarcoma AJCC v7; Stage IV Osteosarcoma AJCC v7; Stage IVA Osteosarcoma AJCC v7; Stage IVB Osteosarcoma AJCC v7; Unresectable Ewing Sarcoma; Unresectable Osteosarcoma
    Interventions
    Cabozantinib S-malate; Laboratory Biomarker Analysis
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2014-12-19
    Completion
    2027-07-23
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Ewing Sarcoma; Metastatic Osteosarcoma; Recurrent Ewing Sarcoma; Recurrent Osteosarcoma +6 more
    InterventionCabozantinib S-malate; Laboratory Biomarker Analysis
    PhasePhase 2
    Registry statusActive not recruiting

  • Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery

    NCT01835145 · start 2013-07-31

    Registered record
    Registry ID
    NCT01835145
    Conditions
    Recurrent Uveal Melanoma; Stage III Uveal Melanoma AJCC v7; Stage IIIA Uveal Melanoma AJCC v7; Stage IIIB Uveal Melanoma AJCC v7; Stage IIIC Uveal Melanoma AJCC v7; Stage IV Uveal Melanoma AJCC v7
    Interventions
    Cabozantinib S-malate; Dacarbazine; Laboratory Biomarker Analysis; Temozolomide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-07-31
    Completion
    2019-11-01
    Enrolment
    47

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Uveal Melanoma; Stage III Uveal Melanoma AJCC v7; Stage IIIA Uveal Melanoma AJCC v7; Stage IIIB Uveal Melanoma AJCC v7 +2 more
    InterventionCabozantinib S-malate; Dacarbazine; Laboratory Biomarker Analysis; Temozolomide
    PhasePhase 2
    Registry statusCompleted

  • Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer

    NCT01835158 · start 2013-07-08

    Registered record
    Registry ID
    NCT01835158
    Conditions
    Clear Cell Renal Cell Carcinoma; Metastatic Kidney Carcinoma; Stage III Renal Cell Cancer AJCC v7; Stage IV Renal Cell Cancer AJCC v7
    Interventions
    Cabozantinib S-malate; Laboratory Biomarker Analysis; Sunitinib Malate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-07-08
    Completion
    Not recorded
    Enrolment
    157

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionClear Cell Renal Cell Carcinoma; Metastatic Kidney Carcinoma; Stage III Renal Cell Cancer AJCC v7; Stage IV Renal Cell Cancer AJCC v7
    InterventionCabozantinib S-malate; Laboratory Biomarker Analysis; Sunitinib Malate
    PhasePhase 2
    Registry statusCompleted

  • Cabozantinib S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus

    NCT01822522 · start 2013-06-21

    Registered record
    Registry ID
    NCT01822522
    Conditions
    Advanced Malignant Solid Neoplasm; HIV Infection; Metastatic Malignant Solid Neoplasm; Recurrent Malignant Solid Neoplasm; Unresectable Solid Neoplasm
    Interventions
    Cabozantinib S-malate; Laboratory Biomarker Analysis; Pharmacological Study
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-06-21
    Completion
    2021-05-12
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Malignant Solid Neoplasm; HIV Infection; Metastatic Malignant Solid Neoplasm; Recurrent Malignant Solid Neoplasm +1 more
    InterventionCabozantinib S-malate; Laboratory Biomarker Analysis; Pharmacological Study
    PhasePhase 1
    Registry statusCompleted

  • Cabozantinib in Men With Castration-Resistant Prostate Cancer

    NCT01703065 · start 2013-06-18

    Registered record
    Registry ID
    NCT01703065
    Conditions
    Adenocarcinoma of the Prostate; Castration-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage III Prostate Cancer; Stage IV Prostate Cancer
    Interventions
    Cabozantinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2013-06-18
    Completion
    2015-09-18
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdenocarcinoma of the Prostate; Castration-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage III Prostate Cancer +1 more
    InterventionCabozantinib
    PhasePhase 2
    Registry statusTerminated

  • Cabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer

    NCT01866410 · start 2013-05-20

    Registered record
    Registry ID
    NCT01866410
    Conditions
    Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer AJCC v7
    Interventions
    Cabozantinib S-malate; Erlotinib Hydrochloride; Laboratory Biomarker Analysis
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-05-20
    Completion
    2018-03-30
    Enrolment
    37

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer AJCC v7
    InterventionCabozantinib S-malate; Erlotinib Hydrochloride; Laboratory Biomarker Analysis
    PhasePhase 2
    Registry statusCompleted

  • Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer

    NCT01811212 · start 2013-05-08

    Registered record
    Registry ID
    NCT01811212
    Conditions
    Poorly Differentiated Thyroid Gland Carcinoma; Recurrent Thyroid Gland Carcinoma; Stage I Thyroid Gland Follicular Carcinoma; Stage I Thyroid Gland Papillary Carcinoma; Stage II Thyroid Gland Follicular Carcinoma; Stage II Thyroid Gland Papillary Carcinoma; Stage III Thyroid Gland Follicular Carcinoma; Stage III Thyroid Gland Papillary Carcinoma; Stage IVA Thyroid Gland Follicular Carcinoma; Stage IVA Thyroid Gland Papillary Carcinoma; Stage IVB Thyroid Gland Follicular Carcinoma; Stage IVB Thyroid Gland Papillary Carcinoma; Stage IVC Thyroid Gland Follicular Carcinoma; Stage IVC Thyroid Gland Papillary Carcinoma; Tall Cell Variant Thyroid Gland Papillary Carcinoma; Thyroid Gland Oncocytic Follicular Carcinoma
    Interventions
    Cabozantinib S-malate; Laboratory Biomarker Analysis
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-05-08
    Completion
    2017-10-09
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPoorly Differentiated Thyroid Gland Carcinoma; Recurrent Thyroid Gland Carcinoma; Stage I Thyroid Gland Follicular Carcinoma; Stage I Thyroid Gland Papillary Carcinoma +12 more
    InterventionCabozantinib S-malate; Laboratory Biomarker Analysis
    PhasePhase 2
    Registry statusCompleted

  • Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer

    NCT01935934 · start 2013-05-08

    Registered record
    Registry ID
    NCT01935934
    Conditions
    Endometrial Adenosquamous Carcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Mixed Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Metastatic Endometrioid Adenocarcinoma; Recurrent Malignant Uterine Corpus Neoplasm; Stage IV Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage; Stage IVA Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage; Stage IVB Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage; Uterine Corpus Carcinosarcoma
    Interventions
    Cabozantinib S-malate; Laboratory Biomarker Analysis; Pharmacological Study
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-05-08
    Completion
    2024-10-24
    Enrolment
    102

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndometrial Adenosquamous Carcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Mixed Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma +6 more
    InterventionCabozantinib S-malate; Laboratory Biomarker Analysis; Pharmacological Study
    PhasePhase 2
    Registry statusCompleted

  • Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery

    NCT01835184 · start 2013-05

    Registered record
    Registry ID
    NCT01835184
    Conditions
    Recurrent Melanoma; Stage IIIA Melanoma; Stage IIIB Melanoma; Stage IIIC Melanoma; Stage IV Melanoma; Unspecified Adult Solid Tumor, Protocol Specific
    Interventions
    cabozantinib-s-malate; vemurafenib; laboratory biomarker analysis; pharmacological study
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2013-05
    Completion
    Not recorded
    Enrolment
    5

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Melanoma; Stage IIIA Melanoma; Stage IIIB Melanoma; Stage IIIC Melanoma +2 more
    Interventioncabozantinib-s-malate; vemurafenib; laboratory biomarker analysis; pharmacological study
    PhasePhase 1
    Registry statusTerminated

  • Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer

    NCT01812668 · start 2013-03

    Registered record
    Registry ID
    NCT01812668
    Conditions
    Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer
    Interventions
    cabozantinib-s-malate; fluorine F 18 d-FMAU; positron emission tomography; pharmacological study; laboratory biomarker analysis
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2013-03
    Completion
    2019-06-18
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer
    Interventioncabozantinib-s-malate; fluorine F 18 d-FMAU; positron emission tomography; pharmacological study +1 more
    PhaseNot applicable
    Registry statusCompleted

  • Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

    NCT01708954 · start 2013-02-13

    Registered record
    Registry ID
    NCT01708954
    Conditions
    Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Non-Small Cell Cancer AJCC v7
    Interventions
    Cabozantinib S-malate; Erlotinib Hydrochloride; Laboratory Biomarker Analysis
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2013-02-13
    Completion
    2027-03-31
    Enrolment
    125

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Non-Small Cell Cancer AJCC v7
    InterventionCabozantinib S-malate; Erlotinib Hydrochloride; Laboratory Biomarker Analysis
    PhasePhase 2
    Registry statusActive not recruiting

  • Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors

    NCT01709435 · start 2012-11-14

    Registered record
    Registry ID
    NCT01709435
    Conditions
    Recurrent Malignant Solid Neoplasm; Recurrent Melanoma; Recurrent Primary Central Nervous System Neoplasm; Recurrent Thyroid Gland Carcinoma; Refractory Malignant Solid Neoplasm; Refractory Primary Central Nervous System Neoplasm; Thyroid Gland Medullary Carcinoma
    Interventions
    Cabozantinib S-malate; Laboratory Biomarker Analysis; Pharmacological Study
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-11-14
    Completion
    2019-12-31
    Enrolment
    41

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Malignant Solid Neoplasm; Recurrent Melanoma; Recurrent Primary Central Nervous System Neoplasm; Recurrent Thyroid Gland Carcinoma +3 more
    InterventionCabozantinib S-malate; Laboratory Biomarker Analysis; Pharmacological Study
    PhasePhase 1
    Registry statusCompleted

  • Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer

    NCT01716715 · start 2012-11-06

    Registered record
    Registry ID
    NCT01716715
    Conditions
    Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma
    Interventions
    Cabozantinib S-malate; Laboratory Biomarker Analysis; Paclitaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-11-06
    Completion
    2019-02-09
    Enrolment
    111

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma
    InterventionCabozantinib S-malate; Laboratory Biomarker Analysis; Paclitaxel
    PhasePhase 2
    Registry statusCompleted